Long-term follow-up of people with beta-thalassemia treated with CS-101
Follows people with beta-thalassemia who received CS-101 for long-term safety and effects.
Plain-language title generated from the registry record
Registry title: A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
Key facts
- Where
- Nanning, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 35 years old?
Source: NCT06717932, who can take part
Where in China
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorrectSequence Therapeutics Co., Ltd
- Trial code
- NCT06717932
- Record updated
- 10 February 2026
- Original description
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961),No investigational drug product will be administered in the study.Read full original descriptionShow less
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With CS-101 Transplantation
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961),No investigational drug product will be administered in the study.
Inclusion: Participants must have received CS-101 infusion in CS-101-01 study; Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form.
Exclusion: There are no exclusion criteria.